Live Breaking News & Updates on Raymond Stevens

Stay updated with breaking news from Raymond stevens. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Phase IIa data re-Structure hopes in oral GLP-1 effort

Given what CEO Raymond Stevens called a space that’s “evolving extremely rapidly,” Structure Therapeutics Inc. chose – rather than wait for next year’s 12-week data – to unblind the eight-week obesity findings with GSBR-1290, an oral glucagon-like peptide-1 (GLP-1) agonist for which the firm also provided a phase IIa update in patients with type 2 diabetes. ....

Raymond Stevens , Structure Therapeutics Inc , Gsbr 1290 , Structure Therapeutics Inc , Glp 1 , Type 2 Diabetes , Glucagon Like Peptide 1 Agonist , Eli Lilly And Co ,